Fisetin, a plant compound sold as a dietary supplement, is being tested to clear worn-out cells that build up with age and feed low-grade inflammation. Support comes from laboratory and mouse work; the few trials comparing short high-dose courses with a placebo found no clear benefit. Short courses appear well tolerated. For health-focused adults, it is a low-cost, mostly low-risk option whose central promise is still a hypothesis. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 7–55 U/L | Safety check; rise stops use |
| AST | 8–48 U/L | Safety check; rise stops use |
| Total bilirubin | 0.1–1.2 mg/dL | Safety check; gates use |
| eGFR | ≥60 mL/min/1.73 m² | Safety check; gates use |
| Fasting glucose | 70–99 mg/dL | Expected change (daily-dose trial); safety with diabetes drugs |
| Fasting insulin | 2.6–24.9 µIU/mL | Expected change (daily-dose trial) |
| INR (warfarin users only) | No established target for fisetin; track change from own baseline | Safety check; change alters warfarin dosing |
| Home blood pressure (antihypertensive users) | Systolic not below 90 mmHg | Detects excessive lowering on dosing days |
| Functional tests (6-minute walk, grip strength) | Sustained gain over own baseline | Defines success; no change after several cycles signals non-response |
Cadence: Baseline before the first course; liver and kidney labs 1–2 weeks after the first course, then every 3–6 months while courses continue; home blood pressure on each dosing day (antihypertensive users); INR within a week of a course (warfarin users); functional tests every 3 months